1. Home
  2. EARN vs IPHA Comparison

EARN vs IPHA Comparison

Compare EARN & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EARN
  • IPHA
  • Stock Information
  • Founded
  • EARN 2012
  • IPHA 1999
  • Country
  • EARN United States
  • IPHA France
  • Employees
  • EARN N/A
  • IPHA N/A
  • Industry
  • EARN Real Estate Investment Trusts
  • IPHA Biotechnology: Pharmaceutical Preparations
  • Sector
  • EARN Real Estate
  • IPHA Health Care
  • Exchange
  • EARN Nasdaq
  • IPHA Nasdaq
  • Market Cap
  • EARN 189.7M
  • IPHA 160.1M
  • IPO Year
  • EARN 2013
  • IPHA 2019
  • Fundamental
  • Price
  • EARN $5.35
  • IPHA $2.18
  • Analyst Decision
  • EARN Buy
  • IPHA Hold
  • Analyst Count
  • EARN 2
  • IPHA 2
  • Target Price
  • EARN $5.88
  • IPHA $2.00
  • AVG Volume (30 Days)
  • EARN 371.7K
  • IPHA 12.3K
  • Earning Date
  • EARN 11-11-2025
  • IPHA 09-17-2025
  • Dividend Yield
  • EARN 18.01%
  • IPHA N/A
  • EPS Growth
  • EARN N/A
  • IPHA N/A
  • EPS
  • EARN N/A
  • IPHA N/A
  • Revenue
  • EARN $35,893,000.00
  • IPHA $14,839,695.00
  • Revenue This Year
  • EARN N/A
  • IPHA $50.89
  • Revenue Next Year
  • EARN $15.93
  • IPHA N/A
  • P/E Ratio
  • EARN N/A
  • IPHA N/A
  • Revenue Growth
  • EARN 43.30
  • IPHA N/A
  • 52 Week Low
  • EARN $4.33
  • IPHA $1.29
  • 52 Week High
  • EARN $7.11
  • IPHA $3.51
  • Technical
  • Relative Strength Index (RSI)
  • EARN 49.61
  • IPHA 60.94
  • Support Level
  • EARN $5.10
  • IPHA $2.07
  • Resistance Level
  • EARN $5.20
  • IPHA $2.28
  • Average True Range (ATR)
  • EARN 0.09
  • IPHA 0.09
  • MACD
  • EARN 0.04
  • IPHA 0.01
  • Stochastic Oscillator
  • EARN 94.20
  • IPHA 69.70

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times. The company primary investment objectives are to generate attractive current yields and risk-adjusted total returns for shareholders. It invest in multiple parts of the CLO capital structure, principally mezzanine debt and equity tranches. Rather than focusing only on short-term current yield, it select investments that it believe will provide a strong total return to drive a sustainable earnings stream over a long-term horizon.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Share on Social Networks: